Kevin Hambly has been appointed vice president, business development and licensing for Catalent Biologics. Mr. Hambly will be responsible for leading business development activities around Catalent’s SMARTag bioconjugation platform, as well as further developing and commercializing Catalent Biologics’ portfolio of technologies.   Mr. Hambly joins the company from Seattle Genetics, where he spent the past nine years, most recently as director of business development responsible for leading out-...